Literature DB >> 11182393

Subareolar injection is a better technique for sentinel lymph node biopsy.

L F Smith1, M J Cross, V S Klimberg.   

Abstract

BACKGROUND: Numerous techniques and materials show accuracy in localizing the sentinel lymph node (SLN). We hypothesized that subareolar injection of material would localize the SLN as effectively as peritumoral injection.
METHODS: Thirty-eight patients were injected with technetium-99 sulfur colloid either peritumorally or subareolarly in addition to the injection of blue dye around the tumor. Radioactive SLNs were localized using a hand-held gamma probe.
RESULTS: Nineteen patients were included in each of the two groups, peritumoral and subareolar. SLNs were found in all patients injected subareolarly and in 18 of 19 injected peritumorally. The false-negative rate was 20% for peritumoral injection and 0% for subareolar injection.
CONCLUSION: The results suggest that subareolar injection was as accurate, if not more accurate, than peritumoral injection for localizing the SLN. This technique is simpler than peritumoral injection and does not require injection under image guidance for nonpalpable lesions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11182393     DOI: 10.1016/s0002-9610(00)00521-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Intraoperative subareolar radioisotope injection for immediate sentinel lymph node biopsy.

Authors:  Rakhshanda Layeeque; Julie Kepple; Ronda S Henry-Tillman; Laura Adkins; Rena Kass; Maureen Colvert; Regina Gibson; Anne Mancino; Soheila Korourian; V Suzanne Klimberg
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

2.  Evaluation of breast lymphatic pathways with indocyanine green fluorescence imaging in patients with breast cancer.

Authors:  Yutaka Ogasawara; Hirokuni Ikeda; Mina Takahashi; Kensuke Kawasaki; Hiroyoshi Doihara
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

3.  Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer.

Authors:  Robert C G Martin; Anees Chagpar; Charles R Scoggins; Michael J Edwards; Lee Hagendoorn; Arnold J Stromberg; Kelly M McMasters
Journal:  Ann Surg       Date:  2005-06       Impact factor: 12.969

4.  Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: preliminary results of a prospective intra-individual comparative study.

Authors:  Sofiane Maza; Ray Valencia; Lilli Geworski; Andreas Zander; Hans Guski; Klaus J Winzer; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-01       Impact factor: 9.236

5.  Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients.

Authors:  Sofiane Maza; Anke Thomas; Klaus J Winzer; Christine Hüttner; Jens-Uwe Blohmer; Maik Hauschild; Matthias Richter; Thomas Krössin; Lilli Geworski; Andreas Zander; Hans Guski; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-27       Impact factor: 9.236

6.  The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.

Authors:  Sarah Pesek; Taka Ashikaga; Lars Erik Krag; David Krag
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

7.  Sentinel lymph node biopsy: technique validation at the Setúbal Medical Centre, Portugal.

Authors:  P Ferreira; R Baía; A António; J Almeida; J Simões; Jc Amaro; C Quintana; L Branco; Mv Rigueira; M Gonçalves; Ev Pereira; Lm Ferreira
Journal:  Ecancermedicalscience       Date:  2009-01-15

8.  Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery.

Authors:  Alberta Ferrari; Paolo Dionigi; Francesca Rovera; Luigi Boni; Giorgio Limonta; Silvana Garancini; Diego De Palma; Gianlorenzo Dionigi; Cristiana Vanoli; Mario Diurni; Giulio Carcano; Renzo Dionigi
Journal:  World J Surg Oncol       Date:  2006-11-20       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.